By Melodie Warner 
 

Watson Pharmaceuticals Inc.'s (WPI) generic version of Teva Pharmaceutical Industries Ltd.'s (TEVA, TEVA.TV) Plan B One-Step emergency contraceptive obtained U.S. Food and Drug Administration approval.

Plan B One-Step, sometimes called the "day-after pill," is used to prevent pregnancy following unprotected intercourse or a known or suspected contraceptive failure.

Watson said it plans to immediately launch its product as Next Choice One Dose.

The company said market-researcher IMS Health puts U.S. sales of Plan B One-Step at $88 million for the year ending May 31.

In April, Watson reported its first-quarter earnings rose 22% as it recorded sharply higher revenue with a boost from new generic drugs and as its branded pharmaceuticals and distribution business also posted double-digit growth.

-Write to Melodie Warner at melodie.warner@dowjones.com

Watson (NYSE:WPI)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Watson Charts.
Watson (NYSE:WPI)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Watson Charts.